Search Results - "Hellmann, Matthew D"

First-Line Immunotherapy for Non-Small-Cell Lung Cancer by Reck, Martin, Remon, Jordi, Hellmann, Matthew D

“…For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to…”
Get full text

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study by Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

“…Summary Background Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy…”
Get full text

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors by Routy, Bertrand, Le Chatelier, Emmanuelle, Derosa, Lisa, Duong, Connie P M, Alou, Maryam Tidjani, Daillère, Romain, Fluckiger, Aurélie, Messaoudene, Meriem, Rauber, Conrad, Roberti, Maria P, Fidelle, Marine, Flament, Caroline, Poirier-Colame, Vichnou, Opolon, Paule, Klein, Christophe, Iribarren, Kristina, Mondragón, Laura, Jacquelot, Nicolas, Qu, Bo, Ferrere, Gladys, Clémenson, Céline, Mezquita, Laura, Masip, Jordi Remon, Naltet, Charles, Brosseau, Solenn, Kaderbhai, Coureche, Richard, Corentin, Rizvi, Hira, Levenez, Florence, Galleron, Nathalie, Quinquis, Benoit, Pons, Nicolas, Ryffel, Bernhard, Minard-Colin, Véronique, Gonin, Patrick, Soria, Jean-Charles, Deutsch, Eric, Loriot, Yohann, Ghiringhelli, François, Zalcman, Gérard, Goldwasser, François, Escudier, Bernard, Hellmann, Matthew D, Eggermont, Alexander, Raoult, Didier, Albiges, Laurence, Kroemer, Guido, Zitvogel, Laurence

“…Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that…”
Get full text

Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images by Jiang, Jue, Hu, Yu-Chi, Liu, Chia-Ju, Halpenny, Darragh, Hellmann, Matthew D., Deasy, Joseph O., Mageras, Gig, Veeraraghavan, Harini

“…Volumetric lung tumor segmentation and accurate longitudinal tracking of tumor volume changes from computed tomography images are essential for monitoring…”
Get full text

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis by Snyder, Alexandra, Nathanson, Tavi, Funt, Samuel A, Ahuja, Arun, Buros Novik, Jacqueline, Hellmann, Matthew D, Chang, Eliza, Aksoy, Bulent Arman, Al-Ahmadie, Hikmat, Yusko, Erik, Vignali, Marissa, Benzeno, Sharon, Boyd, Mariel, Moran, Meredith, Iyer, Gopa, Robins, Harlan S, Mardis, Elaine R, Merghoub, Taha, Hammerbacher, Jeff, Rosenberg, Jonathan E, Bajorin, Dean F

“…Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers,…”
Get full text

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade by Benci, Joseph L., Johnson, Lexus R., Choa, Ruth, Xu, Yuanming, Qiu, Jingya, Zhou, Zilu, Xu, Bihui, Ye, Darwin, Nathanson, Katherine L., June, Carl H., Wherry, E. John, Zhang, Nancy R., Ishwaran, Hemant, Hellmann, Matthew D., Wolchok, Jedd D., Kambayashi, Taku, Minn, Andy J.

“…Interferon-gamma (IFNG) augments immune function yet promotes T cell exhaustion through PDL1. How these opposing effects are integrated to impact immune…”
Get full text

Tumor mutational load predicts survival after immunotherapy across multiple cancer types by Samstein, Robert M., Lee, Chung-Han, Shoushtari, Alexander N., Hellmann, Matthew D., Shen, Ronglai, Janjigian, Yelena Y., Barron, David A., Zehir, Ahmet, Jordan, Emmet J., Omuro, Antonio, Kaley, Thomas J., Kendall, Sviatoslav M., Motzer, Robert J., Hakimi, A. Ari, Voss, Martin H., Russo, Paul, Rosenberg, Jonathan, Iyer, Gopa, Bochner, Bernard H., Bajorin, Dean F., Al-Ahmadie, Hikmat A., Chaft, Jamie E., Rudin, Charles M., Riely, Gregory J., Baxi, Shrujal, Ho, Alan L., Wong, Richard J., Pfister, David G., Wolchok, Jedd D., Barker, Christopher A., Gutin, Philip H., Brennan, Cameron W., Tabar, Viviane, Mellinghoff, Ingo K., DeAngelis, Lisa M., Ariyan, Charlotte E., Lee, Nancy, Tap, William D., Gounder, Mrinal M., D’Angelo, Sandra P., Saltz, Leonard, Stadler, Zsofia K., Scher, Howard I., Baselga, Jose, Razavi, Pedram, Klebanoff, Christopher A., Yaeger, Rona, Segal, Neil H., Ku, Geoffrey Y., DeMatteo, Ronald P., Ladanyi, Marc, Rizvi, Naiyer A., Berger, Michael F., Riaz, Nadeem, Solit, David B., Chan, Timothy A., Morris, Luc G. T.

“…Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer…”
Get full text

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers by Ready, Neal, Hellmann, Matthew D, Awad, Mark M, Otterson, Gregory A, Gutierrez, Martin, Gainor, Justin F, Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S, Chesney, Jason, Orcutt, James, Spigel, David R, Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J, Szustakowski, Joseph D, Green, George, Chang, Han, Ramalingam, Suresh S

“…CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of…”
Get full text

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint by Hellmann, Matthew D, MD, Chaft, Jamie E, MD, William, William N, MD, Rusch, Valerie, Prof, Pisters, Katherine M W, Prof, Kalhor, Neda, MD, Pataer, Apar, MD, Travis, William D, Prof, Swisher, Stephen G, Prof, Kris, Mark G, Dr Prof

“…Summary Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with…”
Get full text

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer by Rizvi, Naiyer A., Hellmann, Matthew D., Snyder, Alexandra, Kvistborg, Pia, Makarov, Vladimir, Havel, Jonathan J., Lee, William, Yuan, Jianda, Wong, Phillip, Ho, Teresa S., Miller, Martin L., Rekhtman, Natasha, Moreira, Andre L., Ibrahim, Fawzia, Bruggeman, Cameron, Gasmi, Billel, Zappasodi, Roberta, Maeda, Yuka, Sander, Chris, Garon, Edward B., Merghoub, Taha, Wolchok, Jedd D., Schumacher, Ton N., Chan, Timothy A.

“…Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants…”
Get full text

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer by Gettinger, Scott, Rizvi, Naiyer A, Chow, Laura Q, Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E, Shepherd, Frances A, Antonia, Scott, Goldman, Jonathan W, Juergens, Rosalyn A, Laurie, Scott A, Nathan, Faith E, Shen, Yun, Harbison, Christopher T, Hellmann, Matthew D

“…Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced…”
Get full text

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial by Paz-Ares, Luis G, Ramalingam, Suresh S, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A, Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A, Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D, Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R, Reck, Martin

“…In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1)…”
Get more information

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers by Caushi, Justina X., Zhang, Jiajia, Ji, Zhicheng, Vaghasia, Ajay, Zhang, Boyang, Hsiue, Emily Han-Chung, Mog, Brian J., Hou, Wenpin, Justesen, Sune, Blosser, Richard, Tam, Ada, Anagnostou, Valsamo, Cottrell, Tricia R., Guo, Haidan, Chan, Hok Yee, Singh, Dipika, Thapa, Sampriti, Dykema, Arbor G., Burman, Poromendro, Choudhury, Begum, Aparicio, Luis, Cheung, Laurene S., Lanis, Mara, Belcaid, Zineb, El Asmar, Margueritta, Illei, Peter B., Wang, Rulin, Meyers, Jennifer, Schuebel, Kornel, Gupta, Anuj, Skaist, Alyza, Wheelan, Sarah, Naidoo, Jarushka, Marrone, Kristen A., Brock, Malcolm, Ha, Jinny, Bush, Errol L., Park, Bernard J., Bott, Matthew, Jones, David R., Reuss, Joshua E., Velculescu, Victor E., Chaft, Jamie E., Kinzler, Kenneth W., Zhou, Shibin, Vogelstein, Bert, Taube, Janis M., Hellmann, Matthew D., Brahmer, Julie R., Merghoub, Taha, Forde, Patrick M., Yegnasubramanian, Srinivasan, Ji, Hongkai, Pardoll, Drew M., Smith, Kellie N.

“…PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can…”
Get full text

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma by Miao, Diana, Margolis, Claire A, Gao, Wenhua, Voss, Martin H, Li, Wei, Martini, Dylan J, Norton, Craig, Bossé, Dominick, Wankowicz, Stephanie M, Cullen, Dana, Horak, Christine, Wind-Rotolo, Megan, Tracy, Adam, Giannakis, Marios, Hodi, Frank Stephen, Drake, Charles G, Ball, Mark W, Allaf, Mohamad E, Snyder, Alexandra, Hellmann, Matthew D, Ho, Thai, Motzer, Robert J, Signoretti, Sabina, Kaelin, Jr, William G, Choueiri, Toni K, Van Allen, Eliezer M

“…Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear cell renal cell…”
Get full text

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 by Ready, Neal, Farago, Anna F, de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D, Schneider, Jeffrey G, Spigel, David R, Moreno, Victor, Chau, Ian, Hann, Christine L, Eder, Joseph Paul, Steele, Nicola L, Pieters, Anne, Fairchild, Justin, Antonia, Scott J

“…For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2,…”
Get more information

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer by Topper, Michael J., Vaz, Michelle, Chiappinelli, Katherine B., DeStefano Shields, Christina E., Niknafs, Noushin, Yen, Ray-Whay Chiu, Wenzel, Alyssa, Hicks, Jessica, Ballew, Matthew, Stone, Meredith, Tran, Phuoc T., Zahnow, Cynthia A., Hellmann, Matthew D., Anagnostou, Valsamo, Strissel, Pamela L., Strick, Reiner, Velculescu, Victor E., Baylin, Stephen B.

“…Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma by Skoulidis, Ferdinandos, Goldberg, Michael E, Greenawalt, Danielle M, Hellmann, Matthew D, Awad, Mark M, Gainor, Justin F, Schrock, Alexa B, Hartmaier, Ryan J, Trabucco, Sally E, Gay, Laurie, Ali, Siraj M, Elvin, Julia A, Singal, Gaurav, Ross, Jeffrey S, Fabrizio, David, Szabo, Peter M, Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Kirov, Stefan, Szustakowski, Joseph, Vitazka, Patrik, Edwards, Robin, Bufill, Jose A, Sharma, Neelesh, Ou, Sai-Hong I, Peled, Nir, Spigel, David R, Rizvi, Hira, Aguilar, Elizabeth Jimenez, Carter, Brett W, Erasmus, Jeremy, Halpenny, Darragh F, Plodkowski, Andrew J, Long, Niamh M, Nishino, Mizuki, Denning, Warren L, Galan-Cobo, Ana, Hamdi, Haifa, Hirz, Taghreed, Tong, Pan, Wang, Jing, Rodriguez-Canales, Jaime, Villalobos, Pamela A, Parra, Edwin R, Kalhor, Neda, Sholl, Lynette M, Sauter, Jennifer L, Jungbluth, Achim A, Mino-Kenudson, Mari, Azimi, Roxana, Elamin, Yasir Y, Zhang, Jianjun, Leonardi, Giulia C, Jiang, Fei, Wong, Kwok-Kin, Lee, J Jack, Papadimitrakopoulou, Vassiliki A, Wistuba, Ignacio I, Miller, Vincent A, Frampton, Garrett M, Wolchok, Jedd D, Shaw, Alice T, Jänne, Pasi A, Stephens, Philip J, Rudin, Charles M, Geese, William J, Albacker, Lee A, Heymach, John V

“…is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that (KL) or (KP) comutations define distinct subgroups of -mutant…”
Get more information

Rational design of anti-GITR-based combination immunotherapy by Zappasodi, Roberta, Sirard, Cynthia, Li, Yanyun, Budhu, Sadna, Abu-Akeel, Mohsen, Liu, Cailian, Yang, Xia, Zhong, Hong, Newman, Walter, Qi, Jingjing, Wong, Phillip, Schaer, David, Koon, Henry, Velcheti, Vamsidhar, Hellmann, Matthew D., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Merghoub, Taha

“…Modulating T cell homeostatic mechanisms with checkpoint blockade can efficiently promote endogenous anti-tumor T cell responses 1 – 11 . However, many…”
Get full text

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis by Datar, Ila, Sanmamed, Miguel F, Wang, Jun, Henick, Brian S, Choi, Jungmin, Badri, Ti, Dong, Weilai, Mani, Nikita, Toki, Maria, Mejías, Luis D, Lozano, Maria D, Perez-Gracia, Jose Luis, Velcheti, Vamsidhar, Hellmann, Matthew D, Gainor, Justin F, McEachern, Kristen, Jenkins, David, Syrigos, Konstantinos, Politi, Katerina, Gettinger, Scott, Rimm, David L, Herbst, Roy S, Melero, Ignacio, Chen, Lieping, Schalper, Kurt A

“…To determine the tumor tissue/cell distribution, functional associations, and clinical significance of PD-1, LAG-3, and TIM-3 protein expression in human…”
Get full text